News
-
BusinessNEW Commencement of a Pre- Feasibility Study for the Commercialization of Sustainable Aviation Fuel, Bio-naphtha, and Renewable Diesel Utilizing Domestic Forest Residues
-
BusinessNEW Mitsubishi Chemical Group Concludes a License Agreement for N-Vinylformamide Manufacturing Technology
-
BusinessNEW JFE Steel, Mitsubishi Gas Chemical, and Mitsubishi Chemical Collaborate to Develop a Carbon Recycling Supply Chain at Mizushima Complex
-
BusinessNEW 【Mitsubishi Tanabe Pharma】Anti-CD19 monoclonal antibody UPLIZNA® for I.V. Infusion 100mg Application for additional indication of immunoglobulin G4-related disease in Japan
-
BusinessNEW 【Mitsubishi Tanabe Pharma】Announcement of NHI Price Listing and Release Date of “Zepbound®”, a Long-Acting GIP/GLP-1 Receptor Agonist, for the Chronic Disease of “Obesity Disease” with Multiple Factors
-
BusinessNEW Commencement of a Pre- Feasibility Study for the Commercialization of Sustainable Aviation Fuel, Bio-naphtha, and Renewable Diesel Utilizing Domestic Forest Residues
-
BusinessNEW Mitsubishi Chemical Group Concludes a License Agreement for N-Vinylformamide Manufacturing Technology
-
BusinessNEW JFE Steel, Mitsubishi Gas Chemical, and Mitsubishi Chemical Collaborate to Develop a Carbon Recycling Supply Chain at Mizushima Complex
-
BusinessNEW 【Mitsubishi Tanabe Pharma】Anti-CD19 monoclonal antibody UPLIZNA® for I.V. Infusion 100mg Application for additional indication of immunoglobulin G4-related disease in Japan
-
BusinessNEW 【Mitsubishi Tanabe Pharma】Announcement of NHI Price Listing and Release Date of “Zepbound®”, a Long-Acting GIP/GLP-1 Receptor Agonist, for the Chronic Disease of “Obesity Disease” with Multiple Factors
-
InformationNEW Transcript (Summary) : Transaction Overview ― Transfer of Mitsubishi Tanabe Pharma Corporation
-
InformationTranscript of Financial Results Presentation for the Third Quarter of Fiscal Year Ending March 31, 2025
-
InformationPresentation Material : Sustainability Briefing 2025
-
InformationConference Video : Transaction Overview ― Transfer of Mitsubishi Tanabe Pharma Corporation
-
InformationPresentation Material : Transaction Overview ー Transfer of Mitsubishi Tanabe Pharma Corporation
-
IR NewsNEW Transcript (Summary) : Transaction Overview ― Transfer of Mitsubishi Tanabe Pharma Corporation
-
IR NewsTranscript of Financial Results Presentation for the Third Quarter of Fiscal Year Ending March 31, 2025
-
IR NewsPresentation Material : Sustainability Briefing 2025
-
TSE Filings“Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 (Under IFRS)” Partial Corrections in Disclosure Matters And Completion of Interim Review for by an Independent Auditor
-
IR NewsConference Video : Transaction Overview ― Transfer of Mitsubishi Tanabe Pharma Corporation
Corporate Information
Group information on Mitsubishi Chemical Group Corporation, which is confronting uncertainty with a continued transformation.
Investor Relations
About IR information of Mitsubishi Chemical Group Corporation, which is enhancing its asset efficiency and refortifying its financial base in an effort to enhance corporate value.
Innovation
We introduce the innovations of the Mitsubishi Chemical Group, which we are pursuing as a driving force that supports sustained growth, across industries and across countries.
Sustainability
The Mitsubishi Chemical Group will work on solving social issues through business activities, contribute to the sustainable development of the global environment and society, and realize the Group’s sustainable growth.
Related Contents
